JP2023530316A5 - - Google Patents

Info

Publication number
JP2023530316A5
JP2023530316A5 JP2022577319A JP2022577319A JP2023530316A5 JP 2023530316 A5 JP2023530316 A5 JP 2023530316A5 JP 2022577319 A JP2022577319 A JP 2022577319A JP 2022577319 A JP2022577319 A JP 2022577319A JP 2023530316 A5 JP2023530316 A5 JP 2023530316A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
compound
mds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037377 external-priority patent/WO2021257532A1/en
Publication of JP2023530316A publication Critical patent/JP2023530316A/ja
Publication of JP2023530316A5 publication Critical patent/JP2023530316A5/ja
Pending legal-status Critical Current

Links

JP2022577319A 2020-06-16 2021-06-15 貧血の治療のためのalk2阻害剤 Pending JP2023530316A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063039742P 2020-06-16 2020-06-16
US63/039,742 2020-06-16
US202063056761P 2020-07-27 2020-07-27
US63/056,761 2020-07-27
US202163152516P 2021-02-23 2021-02-23
US63/152,516 2021-02-23
PCT/US2021/037377 WO2021257532A1 (en) 2020-06-16 2021-06-15 Alk2 inhibitors for the treatment of anemia

Publications (2)

Publication Number Publication Date
JP2023530316A JP2023530316A (ja) 2023-07-14
JP2023530316A5 true JP2023530316A5 (cg-RX-API-DMAC7.html) 2024-06-28

Family

ID=76845323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577319A Pending JP2023530316A (ja) 2020-06-16 2021-06-15 貧血の治療のためのalk2阻害剤

Country Status (13)

Country Link
US (2) US11723899B2 (cg-RX-API-DMAC7.html)
EP (1) EP4164641A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530316A (cg-RX-API-DMAC7.html)
KR (1) KR20230025444A (cg-RX-API-DMAC7.html)
CN (1) CN115968289B (cg-RX-API-DMAC7.html)
AU (1) AU2021292484A1 (cg-RX-API-DMAC7.html)
CA (1) CA3187767A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022003511A1 (cg-RX-API-DMAC7.html)
IL (1) IL298767A (cg-RX-API-DMAC7.html)
MX (1) MX2022015900A (cg-RX-API-DMAC7.html)
PH (1) PH12022553501A1 (cg-RX-API-DMAC7.html)
TW (1) TW202214239A (cg-RX-API-DMAC7.html)
WO (1) WO2021257532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
IL298767A (en) * 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022240948A1 (en) * 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
JP4198183B2 (ja) 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
EP2069313A2 (en) 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metalloprotease inhibitors
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
EP3344613B1 (en) 2015-08-31 2020-03-04 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20220372136A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
IL298767A (en) 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia

Similar Documents

Publication Publication Date Title
US10722512B2 (en) Combinations of histone deacetylase inhibitors and either HER2 inhibitors or PI3K inhibitors
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
JP2022545835A5 (cg-RX-API-DMAC7.html)
JP2022141916A (ja) 癌の治療のための配合剤
JP6532878B2 (ja) 組合せ医薬
JP2022501429A5 (cg-RX-API-DMAC7.html)
JP2021178873A (ja) Hivカプシド阻害剤のコリン塩形態
JP2023062189A5 (cg-RX-API-DMAC7.html)
US10485788B2 (en) Pharmaceutical combinations
EP3703755B1 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer
RU2016122609A (ru) Составы соединений азаиндола
WO2020034916A1 (zh) 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
JP6795518B2 (ja) キナーゼを阻害する組成物及び方法
JP2022538817A5 (cg-RX-API-DMAC7.html)
US20190290627A1 (en) Pim kinase inhibitor combinations
JP2014505107A5 (cg-RX-API-DMAC7.html)
JP2019048822A (ja) Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における2−カルボキサミドシクロアミノウレア誘導体の使用
CN111757731A (zh) 三取代苯并三唑衍生物的使用方法
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
TWI751456B (zh) 癌症療法
WO2021170811A1 (en) Method of treating eye disease using trpv4 antagonists
JP7591283B2 (ja) ブドウ膜黒色腫の治療のための併用療法
JP2019516728A (ja) 抗がん組合せ治療
JP2022177119A5 (cg-RX-API-DMAC7.html)